Quarterly report pursuant to Section 13 or 15(d)

Note 7 - Stockholders' Equity (Details Textual)

v3.24.1.1.u2
Note 7 - Stockholders' Equity (Details Textual)
$ / shares in Units, $ in Thousands
 3 Months Ended
Jan. 05, 2024
USD ($)
$ / shares
shares
Feb. 03, 2023
USD ($)
Jan. 30, 2023
shares
Mar. 31, 2024
USD ($)
$ / shares
shares
Mar. 31, 2023
USD ($)
shares
Jan. 31, 2024
$ / shares
shares
Jan. 09, 2024
shares
Dec. 31, 2023
$ / shares
shares
Nov. 30, 2023
$ / shares
shares
Jan. 31, 2023
$ / shares
shares
Sep. 22, 2022
Dec. 31, 2021
shares
Sep. 13, 2019
$ / shares
Sep. 13, 2016
shares
Preferred Stock, Shares Authorized (in shares)       2,000,000       2,000,000           2,000,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares       $ 0.0001       $ 0.0001            
Common Stock, Shares Authorized (in shares)       200,000,000     200,000,000 75,000,000            
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares       $ 29.5       $ 32.42            
Fair Value Adjustment of Warrants | $       $ 116 $ 878                  
Proceeds from Warrant Exercises | $       $ 4,973 $ 0                  
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)       283                    
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)       0 0                  
Invagen Pharmaceuticals Inc [Member]                            
Contingent Fee, Percentage of Proceeds of Future Financings   7.50%                        
Contingent Fee, Maximum Allowable Amount | $   $ 4,000                        
Restricted Stock Units (RSUs) [Member]                            
Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount | $       $ 100                    
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)       1 year 4 months 24 days                    
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)       45                    
Share-Based Payment Arrangement, Option [Member]                            
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)       1 year 7 months 6 days                    
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $       $ 700                    
Two Thousand Fifteen Incentive Plan [Member]                            
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)     70,223                 3,556    
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)     10 years                      
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)       44,701                    
January 2023 Warrants [Member]                            
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)                   25,871        
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares $ 22.545                 $ 116.25        
Fair Value Adjustment of Warrants | $ $ 100                          
November 2023 Warrants [Member]                            
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)                 194,667          
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares $ 22.545               $ 22.545          
New Series A Warrants [Member]                            
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) 220,538                          
Warrants and Rights Outstanding, Term (Year) 5 years                          
Warrants and Rights Issued Classified as Deemed Dividend | $ $ 600                          
New Series B Warrants [Member]                            
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) 220,538                          
Warrants and Rights Issued Classified as Deemed Dividend | $ $ 4,300                          
Existing Warrants [Member]                            
Proceeds from Warrant Exercises | $ $ 4,500                          
January 2024 Warrant Inducement [Member]                            
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)           25,871                
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares           $ 22.545                
January 2024 Warrant Inducement [Member] | Invagen Pharmaceuticals Inc [Member]                            
Payment of Contingent Fee | $       $ 300                    
May 2024 Warrant Inducement [Member] | Invagen Pharmaceuticals Inc [Member]                            
Payment of Contingent Fee | $       300                    
Shelf [Member]                            
Securities, Remaining Available for Sale, Amount | $       $ 24,900                    
Preferred Class A [Member]                            
Preferred Stock, Shares Authorized (in shares)                           250,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares                         $ 0.0001  
Preferred Stock, Convertible, Conversion Ratio                     1,125